Document:

Exhibit 10.1

    Exhibit
      10.1

    MUTUAL
      SERVICES AGREEMENT

     

    This
      Mutual Services Agreement (this “Agreement”) is made as of June
      23,
      2006, by and between OXIS International, Inc., a Delaware corporation (the
      “OXIS”), and Bio Check, Inc., a California corporation (the “BioCheck”), each of
      them a “Party” and, collectively, the “Parties”. 

    RECITALS

    WHEREAS,
      on
      December 6, 2005, pursuant to a Stock Purchase Agreement, as amended, OXIS
      purchased fifty one percent (51%) of the shares of BioCheck’s common stock from
      each of its shareholders on a pro rata basis for $3,060,000 in cash. Pursuant
      to
      the Stock Purchase Agreement, OXIS will use its reasonable best efforts to
      consummate a follow-on financing transaction to raise additional capital with
      which to purchase the remaining outstanding shares of BioCheck in one or more
      additional closings. If OXIS has not purchased all of the outstanding shares
      of
      BioCheck by December 6, 2006, the earnings before interest, taxes,
      depreciation and amortization expenses, if any, of BioCheck, may be used by
      us
      as partial or complete payment for the remaining outstanding BioCheck shares
      at
      one or more additional closings;

     

    WHEREAS,
      since
      November 2005, OXIS has utilized BioCheck personnel for various services,
      including providing manufacturing management, labor, quality control, packaging
      and shipping of OXIS research assay kit products, research and development
      relating to certain new OXIS research assay kit products for which services
      BioCheck has billed OXIS; and

     

    WHEREAS,
      since
February
      2006
      OXIS
      personnel have provided certain services for BioCheck, including marketing
      and
      sales of BioCheck products, public relations, and certain administrative
      services, for which services OXIS has not billed BioCheck.

     

    NOW,
      THEREFORE,
      in
      consideration of the foregoing recitals and the mutual representations,
      warranties, covenants and promises contained herein, the adequacy and
      sufficiency of which are hereby acknowledged, the Parties hereto agree as
      follows: 

     

    AGREEMENT

    ARTICLE
      1.

    BIOCHECK
      SERVICES, COMPENSATION

     

    1.1
      Services to be Provided by BioCheck.
      BioCheck will provide the following services for OXIS (the
      “BioCheck Services”): 

    (a)
      manufacture certain OXIS research assay kit products listed in Exhibit
      A (“OXIS
      Products”)

    (b)
      senior manufacturing management;

    (c)
      manufacturing labor;

    (d)
      quality control of OXIS products;

    (e)
      quality systems management;

    (f)
      purchasing and receiving of Oxis purchases;

    (g)
      assisting with packaging and shipping of OXIS Products;

    (h)
      providing shipping materials (boxes, foams, ice packs, etc.);

    (i)
      storage of raw materials (chemicals, antibodies, etc.) and lab
      supplies;

    (j)
      storage of packaging materials (kit boxes and foam inserts); and

    (k)
      research and development relating to certain new OXIS research assay kit
      products listed in Exhibit
      B.

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Note:
      Any
      additional service must be agreed by OXIS before it is provided in order to
      be
      compensated.

     

    BioCheck
      shall provide the BioCheck Services in a manner that a reasonable and prudent
      provider engaged in a business similar to BioCheck would perform services
      similar to the BioCheck Services.

     

    1.2
      Product Warranties. BioCheck
      warrants that all OXIS Products produced under Section 1.1 will be free from
      defects in material and workmanship at the time of shipping.

    

    BioCheck
      shall use its best commercial efforts to fill all orders of OXIS Products within
      the time frame agreed upon in writing between the Parties for that particular
      OXIS Product. 

    

    1.3
      Compensation for BioCheck Services.
      OXIS
      shall pay BioCheck in the amount of the regular itemized billing provided by
      BioCheck to OXIS on a monthly basis. BioCheck shall bill OXIS for the aggregate
      hours worked on OXIS projects by BioCheck employees at the actual hourly rate
      per employee plus an overhead surcharge of thirty percent (30%). BioCheck
      shall permit OXIS to audit BioCheck billing statements and, upon reasonable
      request, make available documentation supporting such billing statements.
Compensation
      shall be paid once per month within thirty (30) calendar days of the billing
      date. For invoices dated after the date of this Agreement, taking into
      consideration the effect of Section 1.6 on the unpaid balance, any unpaid
      balance after thirty (30) calendar days of the billing date shall bear interest
      at a rate of five percent (5%) per annum and any unpaid balances after sixty
      (60) calendar days of the billing date shall bear interest at a rate of eight
      percent (8%) per annum. In
      the
      event that OXIS fails to compensate BioCheck for
      its
      undisputed compensation within
      sixty (60) calendar days of the billing date, so
      long
      as BioCheck has provided OXIS with at least fifteen (15) calendar days prior
      notice and an opportunity to cure such breach during such fifteen (15) calendar
      day period, BioCheck
      may terminate this Agreement
      immediately.
      

    

    1.4
      Reimbursement of Expenses.
      BioCheck shall be reimbursed for certain reasonable
      out
      of
      pocket expenses concerning the provision of services pursuant to this Agreement,
      including shipping material costs, monthly cell line storage expense,
      etc.,
      provided that any expenses over $200 per item or $1,000 per month shall
      be
      approved in advance by OXIS, which approval shall not be unreasonably withheld
      or delayed.
      Itemized
      expenses pursuant to this Section 1.4 shall be included in the regular billing
      provided in Section
      1.3.

    

    1.5
      Balance of Payments.
      At the
      end of each month, the amount due by BioCheck to OXIS pursuant to monthly
      billing for services rendered by OXIS for BioCheck (pursuant to Article 2 below)
      shall be deducted from the monthly amount payable by OXIS to
      BioCheck
      if the
      balance of payments would require BioCheck to make a net payment to OXIS in
      a
      particular month.

    

    1.6
      Payment of Outstanding
      Balance.
      OXIS
      agrees to pay BioCheck the outstanding balance due of $73,161.09 for services,
      expenses and overhead incurred during the period between November 2005 and
      April
      30, 2006, after deducting for services provided to BioCheck and expenses
      incurred by OXIS in the provision of such services, if any. Such amount shall
      be
      paid to BioCheck on or before June 30, 2006.

    

    ARTICLE
      2

    OXIS
      SERVICES, COMPENSATION

    

    2.1
      Services to be Provided by OXIS.
      OXIS
      shall provide the following services for BioCheck
      (the
“OXIS Services”):

    

    (a)
      marketing and sales;

    (b)
      website management; and

    (c)
      materials requirements/control systems (to be discussed)

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Note:
      Any
      additional service must be agreed by BioCheck before it is provided in order
      to
      be compensated.

    

    OXIS
      shall provide the OXIS Services in a manner that a reasonable and prudent
      provider engaged in a business similar to OXIS would perform services similar
      to
      the OXIS Services.

    

    2.2
      Compensation for OXIS Services.
      OXIS
      shall bill BioCheck, in the amount of the regular itemized invoices provided
      by
      OXIS to BioCheck on a monthly basis. OXIS shall bill BioCheck for the aggregate
      hours worked on behalf of BioCheck by OXIS employees at the actual hourly rate
      per employee plus an overhead surcharge of thirty percent (30%).
      OXIS
      shall permit BioCheck to audit the OXIS billing statements and, upon reasonable
      request, make available documentation supporting such billing
      statements.
      If an
      amount is due to OXIS pursuant to Section 1.3 above on any billing cycle,
      compensation shall be paid by BioCheck once per month within thirty (30)
      calendar days of the billing date. For invoices dated after the date of this
      Agreement, taking into consideration the effect of Section 2.4 on the unpaid
      balance, any unpaid balance after thirty (30) calendar days of the billing
      date
      shall bear interest at a rate of five percent (5%) per annum and any unpaid
      balances after sixty (60) calendar days of the billing date shall bear interest
      at a rate of eight percent (8%) per annum. In
      the
      event that BioCheck fails to compensate OXIS
      for
      its undisputed compensation
      within
      sixty (60) calendar days of the billing date,
      so
      long
      as OXIS has provided BioCheck with at least fifteen (15) calendar days prior
      notice and an opportunity to cure such breach during such fifteen (15) calendar
      day period, OXIS may
      terminate this Agreement.

    

    2.3
      Reimbursement of Expenses.
      OXIS
      shall be reimbursed for certain reasonable
      out
      of
      pocket expenses concerning the provision of services pursuant to this
      Agreement,
      provided that any expenses over $200
      per
      item or $1,000 per month shall be approved in advance by BioCheck, which
      approval shall not be unreasonably withheld
      or
      delayed.

    

    2.4
      Balance of Payments.
      At the
      end of each month, the amount due by OXIS to BioCheck pursuant to monthly
      billing for services rendered by BioCheck for OXIS (pursuant to Article 2 below)
      shall be deducted from the monthly amount payable by BioCheck to
      OXIS
      if the
      balance of payments would require OXIS to make a net payment to BioCheck in
      a
      particular month.

    

    2.5
      Customer Relationship Responsibilities and Individual
      Corporate Responsibilities.
      For a
      tabular summary of the respective customer relationship responsibilities and
      the
      individual corporate responsibilities of each Party, see Addendum
      A.

    

    ARTICLE
      3.

    CONFIDENTIALITY

    

    3.1 Mutual
      Confidentiality.
      Each
      Party acknowledges that a material term of this Agreement is to keep all
      confidential information belonging to the other Party absolutely confidential
      and protect its release from the public. Each Party agrees not to divulge,
      reveal, report or use, for any purpose, any confidential information which
      the
      other Party has obtained or which was disclosed to the Party receiving the
      information by the other Party, with only exception of that information that
      is
      required by public disclosure rules of the United States of America Securities
      and Exchange Commission. The obligation to protect the confidentially of the
      other Party’s confidential information will survive the termination of this
      Agreement and will continue for a period of three (3) years from the date of
      such termination.

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    3.2 Disclosure.
      A Party
      may disclose any of the confidential information:

    
      	 a.  	 To
              a third party where the Party has consented in writing to such
              disclosure.

    

    
      	        b.  	
              To
                the extent required by law or by the request or requirement of any
                judicial, legislative, administrative or other government body. However,
                the disclosing Party will first have given prompt notice to the other
                Party of any possible or prospective order (or proceeding pursuant
                to
                which any order my result), and the other Party will have been afforded
                a
                reasonable opportunity to prevent or limit any
                disclosure.

            

    

    

    ARTICLE
      4.

    INDEMNIFICATION

     

    4.1
      BioCheck Indemnification Obligation.
      BioCheck
      shall indemnify, defend and hold harmless each of OXIS, its affiliates,
      successors and assigns and their respective sublicensees, directors, officers,
      employees and agents from and against any and all liabilities, damages, losses,
      settlements, penalties, fines, costs and expenses, including, without
      limitation, reasonable outside attorneys’ fees (any of the foregoing to be
      referred to herein as “Damages”)
      of
      whatever kind or nature (but not including taxes), to the extent arising from
      any third party claim, action, suit or proceeding based on: (a) the negligence
      or intentional misconduct of BioCheck or any or its employees or agents in
      the
      performance of its obligations hereunder; (b) a
      material
      breach
      by BioCheck of any term
      of
      this Agreement,
      including without limitation its obligations under Section 1.2, provided that
      such breach has not been cured after thirty (30) calendar days notice of such
      breach has been provided to BioCheck; or
      (c)
      any failure to comply with any Applicable Law (all such claims listed above
      in
      (a) through (c) collectively to be referred to as, “BioCheck
      Claims”),
      in
      each case except to the extent attributable to: (i) the negligence or
      intentional misconduct of OXIS or any or its agents or employees; or
      (ii)
      a
material breach
      by
      OXIS of any
      term of
      this Agreement.

     

    4.2
      OXIS Indemnification Obligation.
      OXIS
      shall indemnify, defend and hold harmless each of BioCheck, its affiliates,
      successors and assigns and their respective sublicensees, directors, officers,
      employees and agents from and against any and all Damages of whatever kind
      or
      nature (but not including taxes), to the extent arising from any third party
      claim, action, suit or proceeding based on: (a) the negligence or intentional
      misconduct of OXIS or any of its agents or employees; or (b) a
      material
      breach
      by OXIS of any term of this Agreement
      (including without limitation its obligations under Sections 1.3 or 1.6),
      provided that such breach has not been cured after thirty (30) calendar days
      notice of such breach has been provided to OXIS,
      (all
      such claims listed above in (a) through (b) collectively to be referred to
      as
“OXIS
      Claims”),
      in
      each case except to the extent attributable to: (i) the negligence or
      intentional misconduct of BioCheck or any of its agents or employees; (ii)
      a
material
      breach
      by
      BioCheck of any
      term of
      this Agreement;
      or
      (iii)
      the failure of BioCheck to manufacture
      or
      supply the research assay test kits referred to in Exhibit A in compliance
      with
      GLP or other Applicable Laws.

     

    4.3
      Process for Indemnification.
      For
      purposes of Sections 4.1 and 4.2, the indemnified Party shall give prompt
      written notice to the indemnifying Party of any suits, claims, actions,
      proceedings or demands by third parties that may give rise to a claim for which
      indemnification may be required under this Section 4.3; provided, however,
      that
      failure to give such notice shall not relieve the indemnifying Party of its
      obligation to provide indemnification hereunder except, if and to the extent
      that such failure materially and adversely affects the ability of the
      indemnifying Party to defend or mitigate the applicable suit, claim, action,
      proceeding or demand. The indemnifying Party shall be entitled to assume the
      defense and control of any such suit, claim, action proceeding or demand at
      its
      own cost and expense; provided, however, that the other Party shall have the
      right to be represented by its own counsel at its own cost in such matters.
      Neither the indemnifying Party nor the indemnified Party shall settle or dispose
      of any such matter in any manner that would materially and adversely affect
      the
      rights or interests of the other Party (including the obligation to indemnify
      hereunder) without the prior written consent of the other Party, which shall
      not
      be unreasonably withheld or delayed. Each Party shall cooperate with the other
      Party and its counsel in the course of the defense of any such suit, claim,
      action, proceeding or demand, such cooperation to include, without limitation,
      using reasonable efforts to provide or make available documents, information
      and
      witnesses. 

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    ARTICLE
      5. 

    MISCELLANEOUS
      PROVISIONS 

    5.1
      Amendments and Waivers.
      This
      Agreement may not be amended, supplemented or modified, except by an agreement
      in writing signed by each of the Parties. Either Party may waive compliance
      by
      the other Party with any term or provision of this Agreement; provided,
      that
      such waiver shall not operate as a waiver of, or estoppel with respect to,
      any
      other or subsequent failure. 

    

    5.2
      Term of Agreement.
      The
      term of this Agreement will begin on the date of this Agreement and will remain
      in force and effect until December 6, 2009, subject to earlier termination
      as
      provided by Section 5.3, unless the Parties agree to extend this Agreement
      by
      mutual written agreement. Upon any termination or expiration of this Agreement,
      neither Party shall have any obligation to perform any services for the other
      Party.

    

    5.3
      Termination Events.
      

     

    (a)
      Without prejudice to other remedies which may be available to the Parties by
      law
      or this Agreement, this Agreement may be terminated:

     

    (i)
      by
      mutual consent of the Parties;

     

    (ii)
      by
      any Party upon at least ninety (90) calendar days advance written notice to
      the
      other Party;

    

    (iii)
      upon the acquisition by OXIS of more than ninety five percent (95%) of the
      outstanding shares of BioCheck;

    

    (iv)
      in
      the event that OXIS breaches any payment or other monetary obligation pursuant
      to Sections 1.3 or 1.6 and does not cure such breach within fifteen (15)
      calendar days from written notice from BioCheck, or in the event that BioCheck
      breaches any payment or other monetary obligation pursuant to Section 2.2 and
      does not cure such breach within fifteen (15) calendar days from written notice
      from OXIS; or

    

    (v)
      in
      the
      event that either Party is in material
      breach of this Agreement (excluding any payment or other monetary breach
      described in Section 5.3(a)(iv)), provided that such breach has not been cured
      after at least thirty (30) calendar days notice of such breach has been provided
      by the non-breaching Party.

     

    (b)
      The
      respective obligations of the Parties pursuant to Sections 1.3, 1.4, 1.6, 2.2
      and 2.3, Articles 3 and 4 and Sections 5.3(b), 5.4 and 5.13 shall survive any
      termination or expiration of this Agreement. 

    

    5.4
      Non
      Compete.
      Other
      than with the express consent of OXIS, which will not be unreasonably withheld
      or delayed, BioCheck warrants that it will not, during the continuance of this
      Agreement or within three (3) years after the termination of this Agreement,
      knowingly market, offer to sell, or sell products competitive with those of
      OXIS
      to existing customers of OXIS.

     

    5.5
      Notices.
      All
      notices, requests, demands and other communications required or permitted under
      this Agreement shall be in writing and shall be deemed to have been duly given,
      made and received (i) when delivered personally or by telecopy, (ii) one (1)
      business day following the day when deposited with a reputable, established
      overnight courier service for delivery to the intended addressee, or (iii)
      three
      (3) business days following the day when deposited with the United States Postal
      Service as first class, registered or certified mail, postage prepaid and
      addressed as set forth below: 

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    If
      to
      OXIS, to: 

     

    OXIS
      International, Inc. 

    323
      Vintage Park Drive, Suite B

    Foster
      City, California 94404

    Attention:
      Chief Executive Officer 

    Facsimile
      No.: (650) 212-2569

     

    If
      to
      BioCheck: 

     

    Bio
      Check, Inc. 

    323
      Vintage Park Drive 

    Foster
      City, California 94404 

    Attention:
      Dr. John Chen 

    Facsimile
      No.: (650) 573-1969

     

    With
      a
      copy, which shall not constitute notice, given in the manner prescribed above,
      to: 

     

    Coblentz,
      Patch, Duffy & Bass LLP 

    One
      Ferry
      Building, Suite 200 

    San
      Francisco, California 94111 

    Attention:
      Paul J. Tauber, Esq. 

    Facsimile
      No.: (415) 989-1663 

    

    Any
      Party
      may alter its notice address by notifying the other Parties of such change
      of
      address in conformity with the provisions of this Section 5.5. 

     

    5.6
      Governing Law.
      This
      Agreement is to be construed in accordance with and governed by the internal
      laws of the State of California, without giving effect to any choice of law
      rule
      that would cause the application of the laws of any jurisdiction other than
      the
      internal laws of the State of California to the rights and duties of the
      Parties. 

     

    5.7
      Jurisdiction; Service of Process. Any
      action or proceeding seeking to enforce any provision of, or based on any right
      arising out of, this Agreement may be brought against any of the Parties only
      in
      the courts of the State of California, County of San Mateo, or, if it has or
      can
      acquire the necessary jurisdiction, in the United States District Court for
      the
      Northern District of California. Each of the Parties consents to the exclusive
      jurisdiction of such courts (and the appropriate appellate courts) in any such
      action or proceeding and waives any objection to venue laid therein. Process
      in
      any action or proceeding referred to in the preceding sentence may be served
      on
      any Party anywhere in the world. 

     

    5.8
      Exhibits, Addendums and Schedules.
      All
      Exhibits, Addendums and Schedules attached hereto are hereby incorporated by
      reference into, and made a part of, this Agreement. 

     

    5.9
      Counterparts.
      This
      Agreement may be executed (including, without limitation, by facsimile
      signature) in one or more counterparts, with the same effect as if the parties
      had signed the same document. Each counterpart so executed shall be deemed
      to be
      an original, and all such counterparts shall be construed together and shall
      constitute one agreement. 

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    5.10
      Severability.
      If any
      provision of this Agreement, or the application of any such provision to any
      person or set of circumstances, shall be determined to be invalid, unlawful,
      void or unenforceable to any extent, the remainder of this Agreement, and the
      application of such provision to persons or circumstances other than those
      as to
      which it is determined to be invalid, unlawful, void or unenforceable, shall
      not
      be impaired or otherwise affected and shall continue to be valid and enforceable
      to the fullest extent permitted by law. 

     

    5.11
      Entire Agreement.
      This
      Agreement, together with its exhibits, schedules and certificates delivered
      under this Agreement contains the entire understanding among the Parties with
      respect to the subject matter hereof and supersedes all prior and
      contemporaneous agreements and understandings, inducements or conditions,
      express or implied, oral or written, among the Parties. The Parties intend
      that
      this Agreement, together with its exhibits, schedules and certificates delivered
      under this Agreement be the complete and exclusive embodiment of their
      agreement, and that any evidence, oral or written, of a prior or contemporaneous
      agreement that alters or modifies this Agreement shall not be admissible in
      any
      proceeding concerning this Agreement. The express terms hereof control and
      supersede any course of performance and/or usage of the trade inconsistent
      with
      any of the terms hereof. 

     

    5.12
      Construction.
      The
      construction of this Agreement shall not take into consideration the Party
      who
      drafted or whose representative drafted any portion of this Agreement, and
      no
      canon of construction shall be applied that resolves ambiguities against the
      drafter of a document. The Parties are sophisticated and have been represented
      by lawyers throughout this transaction who have carefully negotiated the
      provisions hereof. As a consequence, the Parties do not believe the presumption
      of the interpretation of contracts against the drafter of any particular clause
      should be applied in this case and therefore waive its effects. 

     

    5.13
      Recovery of Fees by Prevailing Party.
      If any
      legal action, including, without limitation, an action for arbitration or
      injunctive relief, is brought relating to this Agreement or the breach or
      alleged breach hereof, the prevailing Party in any final judgment or arbitration
      award, or the non-dismissing Party in the event of a voluntary dismissal by
      the
      Party instituting the action, shall be entitled to the full amount of all
      reasonable expenses, including all court costs, arbitration fees and actual
      attorneys’ fees paid or incurred in good faith. 

     

    5.14
      Further Assurances.
      Each
      Party agrees (a) to furnish upon request to each other Party such further
      information, (b) to execute and deliver to each other Party such other
      documents, and (c) to do such other acts and things, all as another Party may
      reasonably request for the purpose of carrying out the intent of this Agreement
      and the services contemplated by this Agreement. 

    

    5.15
      Time of the Essence.
      With
      regard to all dates and time periods set forth or referred to in this Agreement,
      time is of the essence. 

    

    <signature
      page follows>

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, each of the Parties has caused this Mutual Service Agreement
      to
      be executed on its behalf by their respective officers thereunto duly authorized
      all as of the date first written above. 

    
      	 	 	 
	
              “OXIS”

            
	 
	
               

              OXIS
                International, Inc.

               

            
	 	 
	
              By:

            	 	
               

              /s/
                Michael D. Centron

               

            
	 	 	
              Michael
                Centron, its Chief Financial Officer

            
	 
	
              “BioCheck”

            
	 
	
               

              Bio
                Check, Inc.

               

            
	 	 
	
              By:

            	
               

            	
               

              /s/
                John Chen

               

            
	
               

            	
               

            	
              John
                Chen, its Chief Executive
                Officer

            

    

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    EXHIBIT
      A

    

    OXIS
      RESEARCH ASSAY TEST KITS TO BE PRODUCED BY BIOCHECK

    

    

    

      
        	
                Catalog
                  # 

              	
                Product

              	
                Product
                  Description

              
	 	 	 
	
                21010

              	
                SOD-525

              	
                Superoxide
                  Dismutase Assay

              
	
                21011

              	
                GSH-400

              	
                Glutathione
                  Assay

              
	
                21012

              	
                LPO-586

              	
                Lipid
                  Peroxidation Assay

              
	
                21013

              	
                MPO-EIA

              	
                Myeloperoxidase
                  ELISA

              
	
                21014

              	
                plGPx-EIA

              	
                Plasma
                  Glutathione Peroxidase ELISA

              
	
                21015

              	
                Lacto-F
                  EIA

              	
                Lactoferrin
                  ELISA

              
	
                21017

              	
                cGPx-340

              	
                Cellular
                  Glutathione Peroxidase Assay

              
	
                21018

              	
                GR-340

              	
                Glutathione
                  Reductase Assay

              
	
                21019

              	
                8-Isoprostane

              	
                8-epi-Prostaglandin
                  F2alpha Assay 1,2

              
	
                21023

              	
                GSH-420

              	
                Total
                  Glutathione Assay

              
	
                21024

              	
                H2O2-560

              	
                Hydrogen
                  Peroxide assay 1

              
	
                21026

              	
                8-OHdG-EIA

              	
                8-Hydroxy-2’-deoxyguanosine
                  ELISA 1

              
	
                21040

              	
                GSH/GSSG-412

              	
                Reduced
                  and Oxidized Glutathione Assay

              
	
                21041

              	
                Aconitase-340

              	
                Aconitase
                  Assay

              
	
                21042

              	
                Catalase-520

              	
                Catalase
                  Assay

              
	
                21043

              	
                HAE-586

              	
                Hydroxyalkenals
                  Assay 2

              
	
                21044

              	
                MDA-586

              	
                Malondialdehyde
                  Assay

              
	
                21047

              	
                Alpha-1AP-410

              	
                Alpha-1
                  Antiproteinase Assay 2

              
	
                21048

              	
                Urinary
                  8-Epi-Prost. EIA

              	
                Urinary
                  8-Isoprostane ELISA 1

              
	
                21052

              	
                AOP-490

              	
                Antioxidant
                  Potential Assay 1

              
	
                21055

              	
                Nitrotyrosine
                  EIA

              	
                Nitrotyrosine
                  ELISA1

              
	
                22110

              	
                Nitric
                  Oxide

              	
                Total
                  Nitrite Colorimetric (enzymatic) Assay 1,2

              
	
                22111

              	
                Nitric
                  Oxide

              	
                Total
                  Nitrite Colorimetric (non-enzymatic) Assay 1,2

              
	
                22112

              	
                NOS

              	
                Nitric
                  Oxide Synthase (radioactive) 1,2

              
	
                22113

              	
                NOS

              	
                Nitric
                  Oxide Synthase (colorimetric) 1,2

              

      

    

     

    Note:

    1
      =
      OEM

    2
      = being
      phased out

    

    

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    EXHIBIT
      B

    OXIS
      RESEARCH ASSAY TEST KITS

    IN
      RESEARCH AND DEVELOPMENT

    

    

    To
      be determined

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Addendum
      A

     

    Service
      responsibilities for each Party

     

    

    1.
      The
      following are the customer relationship responsibilities for each Party:

    This
      list
      will be updated monthly as needed.

    

    
      	
               

              OXIS
                as customer of BioCheck

               

            	
               

              BioCheck
                as customer of OXIS

               

            
	
              Manufacturing,
                QC and shipping space (including utilities)

            	
              Marketing
                and Sales of BioCheck products and Contract Services

            
	
              Senior
                Manufacturing Management (John Chen)

            	
              Website
                Management for BioCheck

            
	
              Quality
                Systems management (Quality Assurance of OXIS Products - Anna Pao)
                

            	
              Materials
                requirements/control systems for BioCheck (to be
                discussed)

            
	
              Manufacturing
                and QC testing of all OXIS Products (labor)

            	 
	
              Order
                processing, purchasing and customer service for OXIS (Anna
                Pao)

            	 
	
              R
                & D to update and improve OXIS products (John Chen)

            	 
	
              Receiving
                and Shipping services access for OXIS shipments including shipping
                supplies

            	 
	
              Raw
                materials and supplies storage

            	 

    

    

    2.
      For
      purposes of clarity the following are the individual corporate responsibilities
      for each Party to perform for themselves and not to expect or require the other
      Party to this Agreement to perform.

    

    
      	
               

              OXIS
                Responsibilities

               

            	
               

              BioCheck
                Responsibilities:

               

            
	
              Product
                shipments (labor only) of OXIS Products

            	
              All
                manufacturing labor (formulating, dispensing and assembly) of BioCheck
                and
                OXIS products

            
	
              Material
                Requirements/control systems for OXIS

            	
              Quality
                Control of BioCheck and OXIS products

            
	
              Marketing
                and Sales of OXIS and BioCheck products and support for contract
                services
                (new business)

            	
              Product
                Shipments of BioCheck products

            
	
              Customer
                Service of OXIS products

            	
              Quality
                Assurance of BioCheck Products

            
	
              Customer
                Technical Support of OXIS products

            	
              Trade
                Show Attendance for BioCheck Products

            
	
              Bookkeeping
                and Financial reporting of OXIS

            	
              Customer
                Service of BioCheck Products

            
	
              Administrative
                (corporate, legal, human resources, information technology) of OXIS,
                Inc.

            	
              Customer
                Technical Support of BioCheck products

            
	
              Contract
                Services of OXIS products

            	
              R
                & D of all BioCheck products

            
	
              Governmental
                compliance reporting

            	
              Contract
                Services for BioCheck Customers

            
	
              Investor
                Relations for OXIS

            	
              Bookkeeping
                and Financial of BioCheck records

            
	
              Public
                Relations for OXIS

            	
              Patent
                Expense for BioCheck products 

            
	
              Creation
                of Marketing collateral for OXIS products

            	
              Financial
                support (approx. $12K/mo.)

            
	
              Trade
                Show attendance for OXIS products

            	 
	
              Website
                Management for OXIS

            	 
	
              Patent
                Expense for OXIS productsExhibit 10.1(b)

             Schedule of Secured Convertible Note (demand) Issued by
               NCT Group, Inc. to Carole Salkind on June 23, 2006

    Issue Date       Due Date           Principal         Conversion Price
    ----------       --------           ---------         ----------------
     06/23/06        Earlier of:        $550,000       Greater of:  (i) $0.0018;
                     (i) demand;                       or (ii) the par value of
                     or (ii) 12/23/06                  NCT Group, Inc.
                                                       common stock on the
                                                       date of conversion

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00106-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00106-of-00352.parquet"}]]